Latest information


Provigate and Sysmex has entered into a basic agreement for joint development of POCT for glycated albumin

Realizing the World’s First Rapid Home Glycated Albumin Measurement

Provigate, Inc. (Headquarters: Bunkyo, Tokyo; CEO: Koshin Sekimizu) has entered into a basic agreement with Sysmex Corporation (Headquarters: Kobe; President and CEO: Kaoru Asano) concerning the business of compact testing devices and diabetes behavior change support apps using glycated albumin (GA).

GA is an excellent blood glucose-related indicator that sensitively reflects blood glucose fluctuations over a period of a few days to about a week. Measuring it once a week can comprehensively capture the recent blood glucose management status. It has been shown that effective use of this can lead to improvements in blood glucose management for people with diabetes (Notes 1, 2).

Provigate has already realized weekly GA measurement through mail testing and has started offering services as a pilot service (Note 3). However, there is also a high demand for rapid home testing (Point-of-Care Testing, POCT), especially in overseas regions where mail infrastructure is not always reliable, making POCT for GA highly sought after.

Under this basic agreement, the two companies will integrate Provigate’s expertise in sensors and apps with Sysmex’s extensive knowledge in the field of in vitro diagnostics to discuss the potential for joint planning, development, and business collaboration of POCT and apps for GA.

1) Masakazu Aihara, et al. Bi-weekly glycated albumin measurement was useful to encourage behavioral changes in people with type 2 diabetes mellitus. Diabetes Ther 14, 1711–1721 (2023).
2) Jinnouchi H, et al. Efficacy of Self-Review of Lifestyle Behaviors with Once-Weekly Glycated Albumin Measurement in People with Type 2 Diabetes: A Randomized Pilot Study. Diabetes Ther (2024).

Sysmex Corporation
Sysmex is committed to “designing the evolution of healthcare” as stated in its corporate philosophy, the “Sysmex Way.” Since its founding in 1968, Sysmex has focused on laboratory testing, particularly in the fields of blood and urine testing, and currently supports health in over 190 countries and regions. Under its long-term vision of “Shaping the advancement of healthcare,” Sysmex aims to improve the “healthcare journey” of individuals throughout their lives by driving further innovation in laboratory testing and exploring new fields. Sysmex provides new value through its unique technology and solutions, and collaboration with various partners, meeting the universal desire for a healthy, long life.
* “Healthcare Journey” is a registered trademark of Sysmex Corporation.
For more information about Sysmex, please visit

◆ Contact Information

People may think of glucose monitoring as simple as this: "Diabetes is a disease of blood sugar. This is why people with diabetes use glucometer."
However, it's not that simple. Blood sugar measurement has diverse objectives, including diagnosing diabetes, dosing self-injection of insulin, avoiding hypoglycemia due to excessive drug efficacy, and behavior change.
You must choose the appropriate blood sugar measurement method for your purpose.

There are two types of self-blood glucose measurement methods: SMBG (Self-Monitoring of Blood Glucose), which is widely used, and CGM (Continuous Glucose Monitoring), which has become popular in recent years.
These two blood glucose measurement methods are designed mainly for patients who self-inject insulin and other injectable drugs.
Until now, there has been no simple and daily method for measuring blood glucose at home other than these two methods.

Some drugs, such as insulin, are very potent and can cause dangerous hypoglycemia if the dosage is incorrect.
Therefore, for example, those who use insulin must measure their blood glucose accurately before self-injection at home and carefully determine the dose.
After injection, if there are signs of hypoglycemia, it is necessary to measure blood glucose immediately. If necessary, you need to take some sugar to avoid hypoglycemia.
However, both methods have an issue with invasiveness. In addition, they cost a lot. CGM costs at least $60 and needs to be replaced every two weeks, which is also a significant economic burden. SMBG requires frequent measurements, so the total cost becomes significant when accumulated.
Unfortunately, SMBG and CGM are not suitable for everyone due to invasiveness and cost.



Let’s make significant innovations in the era of the healthcare revolution.
We’re looking for talented and enthusiastic individuals to create a better future for everyone.


Feel free to contact us about our services, recruitment and interviews.

Copyright© Provigate, Inc. All Rights Reserved.